Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protein Linked to Aggressive Skin Cancer

By LabMedica International staff writers
Posted on 10 Jul 2019
Almost 300,000 people worldwide develop malignant melanoma each year. More...
The disease is the most serious form of skin cancer and the number of cases reported annually is increasing, making skin cancer one of Sweden's most common forms of cancer.

Over the past ten years, new treatment alternatives that use different methods to strengthen the immune system or attack specific cancer cells have been developed for patients with metastatic skin cancer. The introduction of these treatments is due to an increased understanding of how melanoma develops, but there is still a lack of knowledge about how the tumor cells spread to other parts of the body.

A team of scientists mainly from Lund University (Lund, Sweden) collected lymph node metastatic tissue from 124 patients (48 females, 73 males and three missing information) with a regional metastatic disease and average age at diagnosis of 61 (range 25-86) was used in the quantitative polymerase chain reaction (qPCR) analysis. The team used a multiplicity of methods to obtain their results.

The investigators uncovered an ATP-Dependent RNA Helicase (DDX3X)-driven post-transcriptional program that dictates melanoma phenotype and poor disease prognosis. Through an unbiased analysis of translating ribosomes, they identified the microphthalmia-associated transcription factor, MITF, as a key DDX3X translational target that directs a proliferative-to-metastatic phenotypic switch in melanoma cells. Mechanistically, DDX3X controls MITF mRNA translation via an internal ribosome entry site (IRES) embedded within the 5′ UTR. Through this exquisite translation-based regulatory mechanism, DDX3X steers MITF protein levels dictating melanoma metastatic potential in vivo and response to targeted therapy.

The team noted that that the DDX3X protein does not affect whether or not one develops malignant melanoma, but that it plays a considerable role in the aggressiveness of the tumor. The patient's level of DDX3X can therefore serve as a biomarker for predicting how intractable the disease will be. Göran B. Jönsson, MD, a professor of oncology and pathology, and a senior author of the study, said, “The activity of the MITF gene determines the melanoma cells' specific characteristics, which are then linked to the disease prognosis. The lower the level of DDX3X protein the patient has in the tumor cell, the more aggressive the disease and the worse the prognosis will be.” The study was published on June 18, 2019, in the journal Cell Reports.

Related Links:
Lund University


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.